Sunita Somvanshi
At 80 years old, Lady Joan Branson's death shouldn't have happened. On November 24, 2025, she died from a pulmonary embolism at London's Lister Hospital—a complication that an inquest conclusively found "would likely have been prevented" with a simple, inexpensive medication her doctors never prescribed.
The facts are stark: a fall at home caused Lady Branson pelvic and hip fractures that left her immobilized. Within seven days of admission, blood clots developed in her lungs. Coroner Professor Fiona Wilcox's ruling was unequivocal: the lack of anticoagulation prophylaxis contributed to her death.
What makes this case particularly troubling isn't just the tragedy itself, but what it reveals about gaps in care that extend far beyond one hospital.
The Invisible Patient Safety Crisis
Venous thromboembolism (VTE)—blood clots that can turn fatal—is a leading cause of preventable hospital deaths. Yet fewer than half of hospitalized patients globally receive appropriate prophylaxis, despite two decades of clinical guidelines recommending it. That statistic represents roughly 5 million people annually who face unnecessary risk.
Lady Branson fit the textbook profile for VTE prevention: immobility from fractures is the "biggest risk factor by far," according to haematologist Dr. George Adams, who testified at the inquest. She was "extremely high risk." The standard response—enoxaparin injections at approximately £4 per day—has been proven to reduce clot formation by up to 60% in immobilized patients.
She never received it.
The Accountability Question
Lister Hospital operates under HCA Healthcare, a US-based private hospital chain with £36 billion in annual revenue. The inquest raised questions about whether the facility's protocols aligned with UK clinical standards or prioritized other considerations.
The presence of Lady Branson's daughter, Dr. Holly Branson, at her bedside adds another layer to this failure. As a medical doctor, she possessed the expertise to advocate for her mother's care. Yet she remained unaware that basic prophylactic anticoagulation hadn't been initiated. This communication breakdown—even with medical literacy present in the family—exposes a systemic problem in how hospitals inform patients and families about risk mitigation.
The Economics of Prevention vs. Catastrophe
The math is simple but damning. Preventative anticoagulation costs approximately £4 daily. A single VTE hospitalization averages £12,000 in UK treatment costs, factoring in imaging, emergency interventions, and potential intensive care.
When multiplied across private hospital networks operating internationally, these decisions represent both a medical ethics issue and a corporate liability question. Why aren't chains implementing robust prophylaxis protocols as standard care when prevention costs a fraction of treatment?
What Changes Now?
Lister Hospital has since announced improvements to VTE prevention procedures. But this inquest finding—that preventable death resulted from failure to follow established guidelines—may have implications for private hospital accountability standards globally. When patient deaths can be linked directly to departure from evidence-based protocols, liability exposure increases significantly.
Lady Branson's case illustrates a critical gap: the distance between what medicine can do and what hospitals actually do. Seven days. A fall. An immobilized patient. And a £4-a-day medication that might have changed everything.
That gap deserves scrutiny, not just sympathy.
